# SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC

> **NCT04562337** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shandong Cancer Hospital and Institute** · enrollment: 67 (actual)

## Conditions studied

- Extensive-stage Small Cell Lung Cancer

## Interventions

- **DRUG:** SHR1316
- **DRUG:** Carboplatin
- **DRUG:** Etoposide
- **RADIATION:** Radiation therapy
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT04562337
- **Lead sponsor:** Shandong Cancer Hospital and Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-10-01
- **Primary completion:** 2024-10
- **Final completion:** 2024-10
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04562337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04562337, "SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04562337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*